Mobia Medical has appointed Reza Zadno, Ph.D., to its board of directors as an independent director, effective 14 July 2026. Dr Zadno will also serve on the compensation committee. Dr Zadno brings over 35 years of medical technology experience. He previously served as president and CEO of PROCEPT BioRobotics from February 2020 to September 2025, leading the company through its 2021 IPO. He also led Avedro as president and CEO from September 2016 to November 2020 before its acquisition by Glaukos. Mobia Medical is a commercial-stage medical device company focused on stroke recovery. Its Vivistim Paired VNS System is an FDA-approved implantable solution designed to improve upper limb function in chronic ischaemic stroke survivors.

AUSTIN, Texas, May 07, 2026 (GLOBE NEWSWIRE) -- Mobia Medical, Inc. (Nasdaq: MOBI) (“Mobia Medical”), a commercial-stage medical device company redefining stroke recovery for survivors living with life-altering motor impairments, today announced the pricing of its initial public offering of

Mobia Medical, a commercial-stage medical device company focused on stroke recovery, has priced its initial public offering at $15 per share, offering 10 million shares to raise approximately $150 million in gross proceeds before expenses. The company has also granted underwriters a 30-day option to purchase an additional 1.5 million shares. The company's shares are expected to begin trading on the Nasdaq Global Select Market under the ticker symbol "MOBI" on 8 May 2026, with the offering closing on 11 May 2026. BofA Securities, J.P. Morgan and Goldman Sachs are acting as lead bookrunners for the offering. Mobia Medical's Vivistim Paired VNS System is the first FDA-approved implantable solution designed to improve upper limb function in chronic ischemic stroke survivors with moderate to severe impairments.